Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CM512 injection in chronic spontaneous urticaria
CTR20253564Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing CM512 with Placebo (2 arms). Primary endpoint: Change from baseline in weekly Urticaria Activity Score (UAS7) at Week 16. Started Dec 2025; status: active.
02
Drugs
CM512
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20253564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253564.